• Motivated participation in the conceptional and technological development of gene edited CAR-T cells
• Testing in vitro and in vivo in relevant lymphoma models
• Analysis and preparation of data for reports, manuscripts and thesis diissertation for completion of PhD

• Completed Bachelor’s and Master‘s Degrees in the field of biomedicine, biology, biochemistry, pharmacy or veterinary medicine
• Strong interest in interdisciplinary work and high motivation for a doctorate (“Dr. rer. nat.” or PhD)
• Very good knowledge and practical experience in the field of molecular biology (CRISPR / Cas, vectors), immunology (cell culture, FACS, ELISA) and mouse handling (FELASA B or equivalent certificate)
• MS Office application programs, FlowJo, GraphPad Prism, very good knowledge of English

• A state-of-the-art infrastructure in multidisciplinary, international and new laboratories
• Training in biotechnology and in preclinical research
• Fixed term position from January 1st 2025 until March 31st 2027

The UKK offers a collegial introduction and diverse training and development opportunities as well as an extensive health program for employees. Structured PhD programs are available. There is also a wide range of family support and a day-care center with emergency childcare. In addition, the usual social services of the public service are offered. The UKK is a certified family-friendly university and is committed to promoting women in professional life.

The Translational Immuno-Oncology department (chair Prof. Dr. Renata Stripecke) at the Internal Medicine I (Director Prof. Michael Hallek) of the Cologne University Hospital Cologne develops immunotherapies against cancer. We are engineering chimeric antigen receptor T cells (CAR T cells) that kill lymphoma cells and cells infected with Epstein-Barr Virus (EBV). The CRISPR / Cas9 gene editing technique is currently being used to make CAR T cells more effective, safer and more widely available for patients. These gene-edited CAR T cells will be tested pre-clinically in vitro and in vivo. The clinical development of CAR-T cells against lymphomas will follow as a cooperation with several clinicians at the UKK and the University of Dresden.
 
Further information is available on the internet here.